Priscilla Sugianto

Principal

2020

Vivo Capital is a $8B AUM healthcare-focused investment firm. We are currently investing out of 3 vehicles: our flagship fund IX (late-stage VC, growth, PE) of $1.6B, Innovation Fund II (VC) of ~$330M, and opportunity fund (long-only public vehicle) of $~700M.

Board Member

2023

Board Member

2022

Board Member

2024

Board Observer

2022

Assistant Vice President

2017 - 2020

CBC Group (fka C-Bridge Capital) is a healthcare-dedicated private equity firm with $4.7B of AUM focused on platform-building and buyout investment opportunities across three core areas: biopharma, medtech, and healthcare services. Its flagship strategy features an operationally intensive approach. Its representative investment, includes: I-Mab Biopharma (NASDAQ: IMAB), Everest Medicines (HKEX:1952.HK), among others. CBC also manages a complementary private credit strategy (Royalty Bridge Fund/RBF) dedicated to provide alternative non-dilutive financing to healthcare companies backed by royalties, revenue interest, and other cash flows generated by the sale of healthcare products and services. I was involved in the fund creation, strategy, fundraising, and initial capital deployment. Deals and boards involvement includes (but not limited to): - Everest Medicines (HKEX:1952.HK)- company creation/Series A and Series B. Board observer - AffaMed Therapeutics (Private)- company creation/ JV turned to licensing agreement with Samsung Bioepis/Series A and merger with EverInsight. Board observer - Graybug Vision (NASDAQ: GRAY)- $80M crossover. Boad observer - Paratek (NASDAQ: PRTK)- $60M royalty/credit deal

Business and Corporate Development

2017 - 2020

Part of the founding investor (incubated by CBC group) and team member. Involved in various roles and phases of the company start-up. Worked closely with C-suite (CEO, CFO, CBO, President, etc) and board directors in business development (involved in Immunomedics Trodelvy deal among others), strategy, and financing (series A to crossover to IPO). Everest (1952.HK) was listed in HKEX in 2020 at US$2.7B valuation, just under 3 years since inception in 2017. Prior to the listing, Everest had raised money in private market from top tier investors including: RA Capital, Hillhouse Capital, Decheng Capital, Cormorant, Janus Henderson, Rock Springs Capital, and HBM, to name a few.

Venture Capital- Health Tech/Services

2016 - 2017

Flare Capital is a team of proven healthcare technology venture capital investors who raised one of the industry’s largest dedicated venture capital funds focused exclusively on early stage and emerging growth investments in healthcare technology innovation. https://www.flarecapital.com/our-team